External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

Newamsterdam Pharma  NV / Equity Bottom-Up

<ul><li>NAMS' obicetrapib is a promising drug targeting high cholesterol and cardiovascular disease risk reduction</li><li>Potential FDA approval expected in 2027, despite previous failures of similar CETP inhibitors</li><li>NAMS stock is undervalued, with potential for significant growth, warrant expiration after cardiovascular outcomes data in late-2026.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

NAMS' obicetrapib is a promising drug targeting high cholesterol and cardiovascular disease risk reductionPotential FDA approval expected in 2027, despite previous failures of similar CETP inhibitorsNAMS stock is undervalued, with potential for significant growth, warrant expiration after cardiovascular outcomes data in late-2026.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Newamsterdam Pharma Company (NAMS) - Thursday, Sep 12, 2024

Netherlands

NewAmsterdam Pharma Company N.V. operates as a late-stage clinical biopharmaceutical company.  The company focuses on the development of oral small molecule therapies for cardiovascular and other metabolic diseases.  The company serves patients in the US and Europe.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Newamsterdam Pharma NV (NAMS US)

Newamsterdam Pharma Company (NAMS) - Thursday, Sep 12, 2024

NAMS' obicetrapib is a promising drug targeting high cholesterol and cardiovascular disease risk reduction. Potential FDA approval expected in...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)